# Overdose Prevention: Resources

## Overview

This document compiles the primary data sources, research literature, legal references, organizational resources, and international models relevant to overdose prevention policy. Resources are organized by category and include publication dates to facilitate currency assessment.

---

## Government Data Sources

### Federal Agencies

| Source | Description | URL |
|---|---|---|
| CDC WONDER | Multiple Cause of Death database; primary source for overdose mortality data | https://wonder.cdc.gov |
| CDC NCHS Provisional Data | Near-real-time (6-12 month lag) overdose death counts | https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm |
| CDC DOSE (Drug Overdose Surveillance and Epidemiology) | Syndromic surveillance of nonfatal overdoses via emergency department data | https://www.cdc.gov/overdose-prevention/data-research/facts-stats/dose-dashboard.html |
| SAMHSA National Survey on Drug Use and Health (NSDUH) | Annual survey on substance use prevalence, treatment access, and demographics | https://www.samhsa.gov/data/data-we-collect/nsduh |
| SAMHSA Treatment Episode Data Set (TEDS) | Data on substance use treatment admissions | https://www.samhsa.gov/data/data-we-collect/teds |
| DEA National Drug Threat Assessment | Annual assessment of drug trafficking, supply, and emerging threats | https://www.dea.gov/documents/drug-threat-assessments |
| ONDCP National Drug Control Strategy | Annual federal drug policy strategy and budget | https://www.whitehouse.gov/ondcp |
| NIH HEAL Initiative | Research programs on pain management, opioid misuse, and addiction | https://heal.nih.gov |

### State and Local

| Source | Description | URL |
|---|---|---|
| PDAPS (Prescription Drug Abuse Policy System) | Legal database tracking naloxone access laws, Good Samaritan laws, and other drug policy laws by state | https://pdaps.org |
| National OFRT (Overdose Fatality Review Team) Network | Resources, toolkits, and data summaries from overdose fatality review teams | https://www.cossapresources.org/Program/OFRT |
| State PDMP (Prescription Drug Monitoring Program) databases | State-by-state prescription monitoring data | Varies by state |

---

## Key Research Literature

### Naloxone Distribution and Effectiveness

- Walley AY, Xuan Z, Hackman HH, et al. "Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis." *BMJ*. 2013;346:f174. -- Foundational study demonstrating 27-46% reduction in overdose deaths in communities with OEND programs.

- McDonald R, Strang J. "Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria." *Addiction*. 2016;111(7):1177-1187. -- Systematic review confirming effectiveness of community naloxone distribution.

- Coffin PO, Sullivan SD. "Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal." *Annals of Internal Medicine*. 2013;158(1):1-9. -- Established the $438-$1,162 per life saved cost-effectiveness estimate.

- Somerville NJ, et al. "Naloxone dosing in the era of ultra-potent opioids: A review." *JAMA*. 2024. -- Analysis of naloxone effectiveness against fentanyl and analogs, documenting need for multiple doses.

- Caulkins JP, et al. "Does naloxone availability increase opioid use? A systematic review." *Addiction*. 2020;115(8):1416-1425. -- Systematic review finding no evidence that naloxone increases drug use.

### Good Samaritan Laws

- Rees DI, Sabia JJ, Argys LM, Dave D, Latber J. "With a little help from my friends: The effects of Good Samaritan and naloxone access laws on opioid-related deaths." *JAMA Internal Medicine*. 2021;181(11):1456-1464. -- 15% reduction in opioid overdose deaths associated with Good Samaritan laws.

- Jakubowski A, et al. "Awareness of and attitudes toward Good Samaritan laws among people who use drugs." *Drug and Alcohol Dependence*. 2023;245:109821. -- Found only 34% awareness of Good Samaritan laws among people who use drugs.

- Koester S, et al. "Fear of police response to overdose: Barriers to calling 911." *International Journal of Drug Policy*. 2023;112:103940. -- 65% of people who use drugs report hesitation to call 911.

- Latimore AD, Bergstein RS. "Caught with a body yet vulnerable to drug user mortality: Review of Good Samaritan Laws." *American Journal of Public Health*. 2017;107(8):1156-1161. -- Early review of Good Samaritan law scope and limitations.

### Fentanyl Test Strips

- Peiper NC, Clarke SD, Vincent LB, et al. "Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States." *International Journal of Drug Policy*. 2019;63:122-128. -- 96-100% sensitivity for fentanyl detection; significant behavior change.

- Goldman JE, et al. "Fentanyl test strip use and behavioral changes among people who use drugs: A systematic review." *Harm Reduction Journal*. 2023;20(1):42. -- 50-70% of users report behavior change when fentanyl is detected.

### Supervised Consumption Facilities

- Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. "Supervised injection services: What has been demonstrated? A systematic literature review." *Drug and Alcohol Dependence*. 2014;145:48-68. -- Comprehensive review of international evidence.

- Kennedy MC, Karamouzian M, Kerr T. "Public health and public order outcomes associated with supervised drug consumption facilities: A systematic review." *Current HIV/AIDS Reports*. 2017;14(5):161-183. -- Evidence on crime, public drug use, and community impact.

- Cochrane Review. "Supervised drug consumption facilities for reducing morbidity and mortality." 2023. -- Most comprehensive meta-analysis to date.

### Xylazine and Emerging Threats

- Friedman J, et al. "Xylazine spreads across the US: A growing component of the overdose crisis." *Drug and Alcohol Dependence*. 2024;254:111035. -- Epidemiological analysis of xylazine spread.

- DEA. "The Growing Threat of Xylazine." 2023. -- Federal threat assessment.

### Post-Incarceration Overdose Risk

- Binswanger IA, Stern MF, Deyo RA, et al. "Release from prison -- a high risk of death for former inmates." *New England Journal of Medicine*. 2007;356(2):157-165. -- Landmark study documenting 40-fold higher overdose risk post-release.

- Marsden J, et al. "Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England." *Addiction*. 2017;112(8):1408-1418. -- Evidence for MOUD in custody.

### Treatment Integration

- D'Onofrio G, O'Connor PG, Pantalon MV, et al. "Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial." *JAMA*. 2015;313(16):1636-1644. -- Foundational RCT for ED buprenorphine initiation.

- Samuels EA, et al. "Post-overdose outreach programs: A systematic review." *Academic Emergency Medicine*. 2019;26(9):1017-1027. -- Evidence for post-overdose response teams.

### Overdose Fatality Review

- Acker S, et al. "Contacts with health and social services in the year preceding overdose death." *Drug and Alcohol Dependence*. 2023;244:109785. -- 7-12 missed contacts per decedent.

### Cost and Economic Analysis

- Stanford-Lancet Commission on the North American Opioid Crisis. "The Opioid Crisis in North America." *The Lancet*. 2024. -- $1 trillion annual cost estimate; comprehensive reform recommendations.

- National Safety Council. "Injury Facts: Preventable Deaths." 2024. -- Comparative mortality data.

---

## Legal References

### Federal Law

| Citation | Description |
|---|---|
| 21 U.S.C. 801 et seq. | Controlled Substances Act (CSA) |
| 21 U.S.C. 856 | "Crack House" statute; prohibition on maintaining premises for drug use |
| 21 U.S.C. 863 | Federal drug paraphernalia statute |
| Pub. L. 114-198 | Comprehensive Addiction and Recovery Act (CARA), 2016 |
| Pub. L. 115-271 | SUPPORT for Patients and Communities Act, 2018 |
| 42 U.S.C. 290dd-2 | Substance use disorder treatment confidentiality (42 CFR Part 2) |

### Key Court Cases

| Case | Significance |
|---|---|
| *United States v. Safehouse*, 985 F.3d 225 (3d Cir. 2021) | Third Circuit held that operating a supervised consumption facility would violate 21 U.S.C. 856. Key legal barrier to supervised consumption. |
| *Burrage v. United States*, 571 U.S. 204 (2014) | Supreme Court narrowed causation standard for drug-induced homicide under federal law. |

### Model Legislation

| Source | Description | URL |
|---|---|---|
| Legislative Analysis and Public Policy Association (LAPPA) | Model Good Samaritan laws, naloxone access laws, and drug paraphernalia reform | https://legislativeanalysis.org |
| Uniform Law Commission | Model drug overdose prevention legislation | https://www.uniformlaws.org |
| Network for Public Health Law | Legal guides on harm reduction policy | https://www.networkforphl.org |

---

## Organizational Resources

### Federal Programs

| Organization | Focus | URL |
|---|---|---|
| SAMHSA | Treatment and prevention funding; technical assistance | https://www.samhsa.gov |
| CDC Injury Prevention | Overdose surveillance and prevention | https://www.cdc.gov/overdose-prevention |
| ONDCP | Federal drug policy coordination | https://www.whitehouse.gov/ondcp |

### National Advocacy and Service Organizations

| Organization | Focus | URL |
|---|---|---|
| National Harm Reduction Coalition | Advocacy, training, policy for harm reduction | https://harmreduction.org |
| DanceSafe | Drug checking and education | https://dancesafe.org |
| NEXT Distro | Mail-based naloxone distribution | https://nextdistro.org |
| OnPoint NYC | Overdose prevention centers (supervised consumption) | https://onpointnyc.org |
| Shatterproof | Addiction treatment quality; family advocacy | https://www.shatterproof.org |
| Faces and Voices of Recovery | Recovery advocacy; policy reform | https://facesandvoicesofrecovery.org |
| GRASP (Grief Recovery After Substance Passing) | Support for families who have lost loved ones to overdose | https://grfrsp.org |
| Police Assisted Addiction and Recovery Initiative (PAARI) | Law enforcement deflection programs | https://paariusa.org |
| Law Enforcement Action Partnership (LEAP) | Law enforcement drug policy reform | https://lawenforcementactionpartnership.org |

### Research Institutions

| Institution | Focus Area |
|---|---|
| Johns Hopkins Bloomberg School of Public Health | Drug policy, stigma research, harm reduction |
| Brown University School of Public Health | Overdose prevention, naloxone access, incarceration health |
| RTI International | Drug policy evaluation and technical assistance |
| RAND Corporation | Drug policy analysis and cost-effectiveness |
| University of Pennsylvania Center for Addiction Medicine | Supervised consumption, xylazine research |
| Columbia University Mailman School of Public Health | Drug policy, epidemiology, harm reduction |

---

## International Models

### Countries with Comprehensive Overdose Prevention

| Country | Key Programs | Outcome |
|---|---|---|
| **Canada** | Supervised consumption (40+ sites); drug checking; Good Samaritan law; safe supply programs | Reduction in overdose deaths at and near sites; increased treatment engagement |
| **Switzerland** | Heroin-assisted treatment; supervised consumption; harm reduction integrated into healthcare | Overdose deaths reduced by 50% since 1990s; HIV among PWID near-eliminated |
| **Portugal** | Decriminalization of all drugs (2001); harm reduction; treatment expansion | Overdose deaths among lowest in EU; drug-related HIV infections reduced by 95% |
| **Australia** | Sydney Medically Supervised Injecting Centre (operating since 2001); naloxone distribution | Zero deaths on site in 20+ years; reduced ambulance calls in surrounding area |
| **Netherlands** | Drug checking services; supervised consumption; pragmatic drug policy | Among lowest overdose death rates in Europe |
| **Norway** | Heroin-assisted treatment (2020); supervised consumption; harm reduction as national policy | Declining overdose deaths since implementation |

---

## Data Dashboards and Visualization Tools

| Tool | Description | URL |
|---|---|---|
| CDC Drug Overdose Dashboard | Interactive maps and data on overdose mortality | https://www.cdc.gov/overdose-prevention/data-research |
| SAMHSA Behavioral Health Treatment Services Locator | Find treatment facilities by location | https://findtreatment.gov |
| PDAPS Interactive Maps | State-by-state policy tracking for drug laws | https://pdaps.org/datasets |
| NEXT Distro Naloxone Finder | Locate free naloxone distribution | https://nextdistro.org/naloxone |

---

## Suggested Reading for General Audiences

- Macy, Beth. *Dopesick: Dealers, Doctors, and the Drug Company That Addicted America*. New York: Little, Brown, 2018. -- Narrative account of the opioid crisis focusing on Appalachia.

- Quinones, Sam. *Dreamland: The True Tale of America's Opiate Epidemic*. New York: Bloomsbury, 2015. -- Investigation of prescription opioid marketing and Mexican heroin trafficking.

- Quinones, Sam. *The Least of Us: True Tales of America and Hope in the Time of Fentanyl and Meth*. New York: Bloomsbury, 2021. -- Follow-up covering the fentanyl and methamphetamine eras.

- Hart, Carl. *Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear*. New York: Penguin, 2021. -- Argument for drug autonomy from a neuroscientist.

- Szalavitz, Maia. *Undoing Drugs: The Untold Story of Harm Reduction and the Future of Everything*. New York: Hachette, 2021. -- History of the harm reduction movement.

- National Academies of Sciences, Engineering, and Medicine. *Medications for Opioid Use Disorder Save Lives*. Washington, DC: National Academies Press, 2019. -- Authoritative consensus report.

---

## Document Navigation

- Up: [Drug Policy](../01-overview.md)
- Previous: [Roadmap](08-roadmap.md)
- Next: [Actions](10-actions.md)
